Atazanavir/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults

Future Virology

Volumn 6, Issue 2, 2011, Pages 157-177

  Achenbach, Chad J ^a   Darin, Kristin M ^a   Murphy, Robert L ^a,b   Katlama, Christine ^b,c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b SORBONNE UNIVERSITÉ   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

antiretroviral therapy; atazanavir; HIV; protease inhibitor; ritonavir

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FAMOTIDINE; FOSAMPRENAVIR; FOSAMPRENAVIR PLUS RITONAVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; OMEPRAZOLE; PEGINTERFERON; RALTEGRAVIR; RIBAVIRIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TENOFOVIR;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; DIARRHEA; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG MILK LEVEL; DRUG PENETRATION; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TRANSFORMATION; DRUG TREATMENT FAILURE; DRUG URINE LEVEL; DRUG WITHDRAWAL; END STAGE LIVER DISEASE; EYE JAUNDICE; FOLLOW UP; FOOD DRUG INTERACTION; GENOTYPE; GILBERT DISEASE; GLUCOSE BLOOD LEVEL; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERBILIRUBINEMIA; IC 50; INFRARED SPECTROPHOTOMETRY; INSULIN RESISTANCE; JAUNDICE; KIDNEY FAILURE; LIVER FAILURE; LIVER METABOLISM; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MIXED INFECTION; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NAUSEA; NEPHROLITHIASIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PLACENTAL TRANSFER; PREGNANCY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RASH; SEMINAL PLASMA; SIDE EFFECT; SINGLE DRUG DOSE; STEADY STATE; STOMACH PH; STONE ANALYSIS; SUBCUTANEOUS FAT; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; VIRION; VIRUS INHIBITION; VIRUS LOAD;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79952591356     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/fvl.10.89     Document Type: Article

References (114)

1. Palella FJ Jr, Delaney KM, Moorman AC et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N. Engl. J. Med. 338(13), 853-860 (1998). (Pubitemid 28135961)
2. Mocroft A, Ledergerber B, Katlama C et al.: Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 362(9377), 22-29 (2003). (Pubitemid 36835816)
3. Thompson M, Aberg J, Cahn P et al.: Antiretroviral treatment of adult HIV infection: 2010 recommendations of the international AIDS society-USA panel. JAMA 304(3), 321 (2010).
4. Robinson BS, Riccardi KA, Gong YF et al.: BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob. Agents Chemother. 44(8), 2093-2099 (2000). (Pubitemid 30484432)
5. Alatrakchi N, Di Martino V, Thibault V, Autran B: Strong CD4 Th1 responses to HIV and hepatitis C virus in HIV-infected long-term non-progressors co-infected with hepatitis C virus. AIDS 16(5), 713-717 (2002). (Pubitemid 34274461)
6. Agarwala S, Grasela D, Child M, Geraldes M, Geiger M, OMara E: Characterization of the steady-state pharmacokinetic (PK) profile of atazanavir (ATV) beyond the 24-hour dosing interval. Presented at: 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France, 8-11 July 2003.
7. Welage LS, Carver PL, Revankar S, Pierson C, Kauffman CA: Alterations in gastric acidity in patients infected with human immunodeficiency virus. Clin. Infect. Dis. 21(6), 1431-1438 (1995). (Pubitemid 26066634)
8. Omara E, Mummaneni V, Randall D et al.: BMS-232632: a summary of multiple dose pharmacokinetic, food effect and drug interaction studies in healthy subjects. Presented at: 7th Conference on Retroviruses and Opportunistic Infections. CA, USA 30 Jan-2 Feb 2000.
9. Randall D, Agarwala S, Mummanemi V: Multiple-dose pharmacokinetics of atazanavir in healthy subjects: a summary of food effect and drug interaction studies. Presented at: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. CA, USA, 27-30 September 2002.
10. Giguere P, Burry J, Beique L et al.: The effect of food on the pharmacokinetics of atazanavir/ritonavir 300/100 mg daily in HIV-infected patients. Presented at: 11th Workshop on Clinical Pharmacology of HIV Therapy. Sorrento, Italy, 7-9 April 2010.
11. Barrail-Tran A, Mentre F, Cosson C et al.: Influence of a-1 glycoprotein acid concentrations and variants on atazanavir pharmacokinetics in HIV-infected patients included in the ANRS 107 trial. Antimicrob. Agents Chemother. 54(2), 614-619 (2010).
12. Van Leeuwen E, Ter Heine R, Van Der Veen F, Repping S, Beijnen JH, Prins JM: Penetration of atazanavir in seminal plasma of men infected with human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 51(1), 335-337 (2007). (Pubitemid 46047724)
13. Best BM, Letendre SL, Brigid E et al.: Low atazanavir concentrations in cerebrospinal fluid. AIDS 23(1), 83-87 (2009).
14. Letendre S, FitzSimons C, Ellis R et al.; Correlates of CSF viral loads in 1221 volunteers of the charter cohort. Presented at: 17th Conference on Retroviruses and Opportunistic Infections. CA, USA 16-19 February 2010.
15. Letendre S, Marquie-Beck J, Capparelli E et al.: Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch. Neurol. 65(1), 65-70 (2008).
16. Tozzi V, Balestra P, Salvatori MF et al.: Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on hiv-associated neurocognitive disorders. J. Acquir. Immune Defic. Syndr. 52(1), 56-63 (2009).
17. Anderson PL, Aquilante CL, Gardner EM et al.: Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors. J. Antimicrob. Chemother. 64(5), 1071-1079 (2009).
18. Ter Heine R, Hillebrand MJ, Rosing H et al.: Identification and profiling of circulating metabolites of atazanavir, a HIV protease inhibitor. Drug Metab. Dispos. 37(9), 1826-1840 (2009).
19. Dickinson L, Boffito M, Back D et al.: Population pharmacokinetics of ritonavir-boosted atazanavir in hiv-infected patients and healthy volunteers. J. Antimicrob. Chemother. 63(6), 1233-1243 (2009).
20. Colombo S, Buclin T, Cavassini M et al.: Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection. Antimicrob. Agents Chemother. 50(11), 3801-3808 (2006). (Pubitemid 44684896)
21. Solas C, Gagnieu MC, Ravaux I et al.: Population pharmacokinetics of atazanavir in human immunodeficiency virus-infected patients. Ther. Drug Monit. 30(6), 670-673 (2008).
22. Janneh O, Anwar T, Jungbauer C et al.: P-glycoprotein, multidrug resistance-associated proteins and human organic anion transporting polypeptide influence the intracellular accumulation of atazanavir. Antivir. Ther. 14(7), 965-974 (2009).
23. Bousquet L, Roucairol C, Hembury A et al.: Comparison of ABC transporter modulation by atazanavir in lymphocytes and human brain endothelial cells: ABC transporters are involved in the atazanavir-limited passage across an in vitro human model of the blood-brain barrier. AIDS Res. Hum. Retroviruses 24(9), 1147-1154 (2008).
24. Lucia MB, Golotta C, Rutella S, Rastrelli E, Savarino A, Cauda R: Atazanavir inhibits P-glycoprotein and multidrug resistance-associated protein efflux activity. J. Acquir. Immune Defic. Syndr. 39(5), 635-637 (2005). (Pubitemid 41098483)
25. Ofotokun I, Chuck SK, Hitti JE: Antiretroviral pharmacokinetic profile: a review of sex differences. Gend. Med. 4(2), 106-119 (2007). (Pubitemid 47248489)
26. Umeh O, Currier J, Park JG et al.; the A5223 Study Group: Sex differences in lopinavir/ ritonavir soft gel capsule pharmacokinetics among HIV-infected females and males. Presented at: 14th Conference on Retroviruses and Opportunistic Infections. CA, USA, USA, 25-28 February 2007.
27. King JR, Kakuda TN, Paul S, Tse MM, Acosta EP, Becker SL: Pharmacokinetics of saquinavir with atazanavir or low-dose ritonavir administered once daily (ASPIRE I) or twice daily (ASPIRE II) in seronegative volunteers. J. Clin. Pharmacol. 47(2), 201-208 (2007). (Pubitemid 46146486)
28. Von Hentig N, Babacan E, Lennemann T et al.: The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors. J. Antimicrob. Chemother. 62(3), 579-582 (2008).
29. Lechelt M, Lyons F, Clarke A, Magaya V, Issa R, De Ruiter A: Human placental transfer of atazanavir: a case report. AIDS 20(2), 307 (2006).
30. Ivanovic J, Nicastri E, Anceschi MM et al.: Transplacental transfer of antiretroviral drugs and newborn birth weight in HIV-infected pregnant women. Curr. HIV Res. 7(6), 620-625 (2009).
31. Mirochnick M, Stek A, Capparelli E et al.; P1026s Protocol Team: Atazanavir pharmacokinetics with and without tenofovir during pregnancy. Presented at: T-140. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada, 8-11 February 2009.
32. Ripamonti D, Cattaneo D, Maggiolo F et al.: Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. AIDS 21(18), 2409-2415 (2007). (Pubitemid 350145172)
33. Ripamonti D, Cattaneo D, Davolio A et al.: Steady state pharmacokinetics of ritonavir-boosted atazanavir in 31 pregnant women before and after delivery. Presented at: 17th Conference on Retroviruses and Opportunistic Infections. CA, USA, 16-19 February 2010.
34. Spencer L, Neely M, Mordwinkin N et al.: Intensive PK of zidovudine (AZT), lamivudine (3TC), and atazanavir (ATV) and HIV-1 viral load in breast milk and plasma in HIV+ women receiving HAART therapy. Presented at: 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada, 8-11 February 2009.
35. Mirochnick M, Best BM, Stek AM et al.: Lopinavir exposure with an increased dose during pregnancy. J. Acquir. Immune Defic. Syndr. 49(5), 485-491 (2008).
36. Mirochnick M, Capparelli E: Pharmacokinetics of antiretrovirals in pregnant women. Clin. Pharmacokinet. 43(15), 1071-1087 (2004). (Pubitemid 40013177)
37. Eley T, Vandeloise E, Child M et al.; the Atazanavir 182 Pregnancy Study Group: Steady state pharmacokinetics and safety of atazanavir after treatment with ATV 300 mg once daily / ritonavir 100 mg once daily + ZDV/3TC during the third trimester in HIV+ women. Presented at: 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada, 8-11 February 2009.
38. Kaul S, Bassi K, Damle B et al.: Pharmacokinetic evaluation of the combination of atazanavir, enteric coated didanosine and tenofovir disoproxil fumarate for a once daily antiretroviral regimen. Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. IL, USA, 13-17 September 2003.
39. Guaraldi G, Cocchi S, Motta A et al.: A pilot study on the efficacy, pharmacokinetics and safety of atazanavir in patients with end-stage liver disease. J. Antimicrob. Chemother. 62(6), 1356-1364 (2008).
40. Barreiro P, Rodriguez-Novoa S, Labarga P et al.: Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C. J. Infect. Dis. 195(7), 973-979 (2007). (Pubitemid 46452102)
41. Guaraldi G, Cocchi S, Motta A et al.: Efficacy and safety of atazanavir in patients with end-stage liver disease. Infection 37(3), 250-255 (2009).
42. Hermida Donate JM, Quereda C, Moreno A et al.: Efficacy and safety of atazanavir in HIV-infected patients with liver cirrhosis. Presented at: 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Sydney, Australia, 22-25 July 2007.
43. Agarwala S, Eley T, Child M et al.: Pharmacokinetics of atazanavir in severely renally impaired subjects including those on hemodialysis. Presented at: 8th International Workshop on Clinical Pharmacology of HIV Therapy. Abstract no. 2. Budapest, Hungary, 16-18 April 2007.
44. Taburet AM, Piketty C, Chazallon C et al.: Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 48(6), 2091-2096 (2004). (Pubitemid 38691603)
45. Von Hentig N, Dauer B, Haberl A et al.: Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults. Eur. J. Clin. Pharmacol. 63(10), 935-940 (2007). (Pubitemid 47387910)
46. Stohr W, Back D, Dunn D et al.: Factors influencing lopinavir and atazanavir plasma concentration. J. Antimicrob. Chemother. 65(1), 129-137 (2010).
47. Molina JM, Andrade-Villanueva J, Echevarria J et al.: Once-daily atazanavir/ritonavir versus twice-daily lopinavir ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the castle study. Lancet 372(9639), 646-655 (2008).
48. Agarwala S, Eley T, Villegas C et al.: Pharmacokinetic interaction between tenofovir and atazanavir coadministered with ritonavir in healthy subjects. Presented at: 6th International Workshop on Clinical Pharmacology of HIV Therapy. Quebec, Canada, 28-30 April 2005.
49. Kiser JJ, Fletcher CV, Flynn PM et al.: Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection. Antimicrob. Agents Chemother. 52(2), 631-637 (2008). (Pubitemid 351170838)
50. Vincent I, Barrail A, Piketty C et al.: Pharmacokinetic parameters of tenofovir when combined with atazanavir/ritonavir in hiv-infected patients with multiple treatment failures: A substudy of puzzle 2-ANRS 107 trial. Presented at: 6th International Workshop on Clinical Pharmacology of HIV Therapy. Quebec, Canada, 28-30 April 2005.
51. Agarwala S, Persson A, Eley T et al.: Effect of famotidine 20- and 40-mg dosing regimens on the bioavilability of atazanavir with ritonavir in combination with tenofovir in healthy subjects. Presented at: 14th Conference on Retroviruses and Opportunistic Infections. CA, USA, 25-28 February 2007.
52. Wang X, Chung E, Mahnke L et al.: Effects of famotidine on the pharmacokinetics of atazanavir when given with ritonavir with or without tenofovir in HIV-infected subjects. Presented at: 10th International Workshop on Clinical Pharmacology of HIV Therapy. Amsterdam, The Netherlands 15-17, April 2009.
53. Agarwala S, Gray K, Wang Y, Grasela D: Pharmacokinetic effect of omeprazole on atazanavir coadminstered with ritonavir in healthy subjects. Presented at: 12th Conference on Retroviruses and Opportunistic Infections. MA, USA, 22-25 February 2005.
54. Luber A, Brower R, Peloquin C, Frank I: Steady state pharmacokinetics (PK) of once daily fosamprenavir/ritonavir (FPV/R) and atazanavir/ritonavir (ATV/R) alone and in combination with 20 mg once daily of omeprazole (OMP) in healthy volunteers. Presented at: 7th International Workshop on Clinical Pharmacology of HIV Therapy. Lisbon, Portugal 20-22 April 2006.
55. Zhu L, Persson A, Mahnke L et al.: Effect of low-dose omeprazole (20 mg daily) on the pharmacokinetics of multiple-dose atazanavir with ritonavir in healthy subjects. J. Clin. Pharmacol. DOI: 10.1177/0091270010367651 (2010) (Epub ahead of print).
56. Becker S: Atazanavir: improving the HIV protease inhibitor class. Expert Rev. Anti. Infect. Ther. 1(3), 403-413 (2003). (Pubitemid 38855105)
57. Bentué-Ferrer D, Arvieux C, Tribut O, Ruffault A, Bellissant E: Clinical pharmacology, efficacy and safety of atazanavir: a review. Expert Opin. Drug Metab. Toxicol. 5(11), 1455-1468 (2009).
58. Busti AJ, Hall RG, Margolis DM: Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy 24(12), 1732-1747 (2004). (Pubitemid 39578961)
59. Croom KF, Dhillon S, Keam SJ: Atazanavir: a review of its use in the management of HIV-1 infection. Drugs 69(8), 1107-1140 (2009).
60. Orrick JJ, Steinhart CR: Atazanavir. Ann. Pharmacother. 38(10), 1664-1674 (2004).
61. Piliero PJ: Atazanavir: a novel once-daily protease inhibitor. Drugs Today 40(11), 901-912 (2004). (Pubitemid 40095997)
62. Murphy RL, Sanne I, Cahn P et al.: Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS 17(18), 2603-2614 (2003). (Pubitemid 38402338)
63. Wood R, Phanuphak P, Cahn P et al.: Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. J. Acquir. Immune Defic. Syndr. 36(2), 684-692 (2004). (Pubitemid 38685962)
64. Malan DR, Krantz E, David N et al.: Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients. J. Acquir. Immune Defic. Syndr. 47(2), 161-167 (2008). (Pubitemid 351172182)
65. Horberg M, Klein D, Hurley L et al.: Efficacy and safety of ritonavir-boosted and unboosted atazanavir among antiretroviral-naive patients. HIV Clin. Trials 9(6), 367-374 (2008).
66. Santoro MM, Bertoli A, Lorenzini P et al.: Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the care study. AIDS Patient Care STDS 22(1), 7-16 (2008).
67. Elion R, Cohen C, Ward D et al.: Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naïve patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/ emtricitabine given once daily. HIV Clin. Trials 9(4), 213-224 (2008).
68. Elion R, Dejesus E, Sension M et al.: Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naive patients: a 48-week pilot study. HIV Clin. Trials 9(3), 152-163 (2008). (Pubitemid 351892869)
69. Johnson M, Grinsztejn B, Rodriguez C et al.: 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir ritonavir in patients with multiple virologic failures. AIDS 20(5), 711-718 (2006). (Pubitemid 43884298)
70. Landman R, Capitant C, Descamps D et al.: Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study. J. Antimicrob. Chemother. 64(1), 118-125 (2009).
71. Molina J-M, Andrade-Villanueva J, Echevarria J et al.: Once-daily atazanavir/ ritonavir versus twice-daily lopinavir/ ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 372(9639), 646-655 (2008).
72. Molina J-M, Andrade-Villanueva J, Echevarria J et al.: Once-daily atazanavir/ ritonavir compared with twice-daily lopinavir ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J. Acquir. Immune Defic. Syndr. 53(3), 323-332 (2010).
73. Smith KY, Weinberg WG, Dejesus E et al.: Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/ emtricitabine, for the initial treatment of HIV infection: 48-week results of alert. AIDS Res. Ther. 5, 5 (2008)
74. Squires KE, Young B, Dejesus E et al.: Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients. HIV Clin. Trials 11(2), 69-79 (2010).
75. Squires Ke, Young B, Dejesus E et al.: Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in hiv-infected patients. AIDS 24(13), 2019-2027 (2010).
76. Daar E, Tierney C, Fischl M et al.; ACTG A5202 Study Team: ACTG 5202: final results of ABC/3TC or TDF/FTC with either EFV or ATV/R in treatment-naive HIV-infected patients. Presented at: 17th Conference on Retroviruses and Opportunistic Infections. CA, USA 16-19 February 2010.
77. Cohen C, Shamblaw D, Ruane P, Elion R et al.: Single-tablet, fixed-dose regimen of elvitegravir/emtricitabine/tenofovir disoproxil fumarate/GS-9350 achieves a high rate of virologic suppression and GS-9350 is an effective booster. Presented at: 17th Conference on Retroviruses and Opportunistic Infections. CA, USA 16-19 February 2010.
78. Cooper D: Safety and efficacy of three different combinaton antiretroviral regimens as initial therapy for HIV infection: week 48 data from a randomized, open-label study (#LBPEB09).Presented at: 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa, 19-22 July 2009.
79. Soriano V, Köppe S, Migrone H, Lutz T, Opravil M et al.: Prospective randomized comparison of nevirapine and atazanavir/ ritonavir both combined with tenofovir DF/ emtricitabine in treatment-naive HIV-1 infected patients: ARTEN study week 48 results (#lbpeb07).Presented at: 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa, 19-22 July 2009.
80. Piketty C, Gerard L, Chazallon C et al.: Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial. Antivir. Ther. 11(2), 213-221 (2006).
81. Wilkin TJ, Mckinnon JE, Dirienzo AG et al.: Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes. J. Infect. Dis. 199(6), 866-871 (2009).
82. Karlström O, Josephson F, Sönnerborg A: Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy. J. Acquir. Immune Defic. Syndr. 44(4), 417-422 (2007). (Pubitemid 46555376)
83. Deluca A, Bracciale L, Doino M, Fabbiani M et al.: Safety and efficacy of treatment simplification to atazanavir/ritonavir plus lamivudine in patients on two NRTIS plus atazanavir/ritonavir with optimal virologic control: 24 weeks results from a pilot study (atazanavir and lamivudine simplification study, ATLAS) (#THLBB207).Presented at: XVIII International AIDS Conference. Vienna, Austria, 18-23 July 2010.
84. Mills A, Mildvan D, Podzamczer D et al.: Safety and immunovirological activity of once daily maraviroc (MVC) in combination with ritonavir-boosted atazanavir (ATV/R) compared with emtricitabine 200mg/ tenofovir 300mg QD (TDF/FTC) + ATV/R in treatment-naïve patients infected with CCR5-tropic HIV-1 (study a4001078): a week 24 planned interim analysis (#THLBB203).Presented at: XVIII International AIDS Conference. Vienna, Austria,18-23 July 2010.
85. Kozal M, Lupo S, Dejesus E, Molina J et al.: The SPARTAN study: a pilot study to assess the safety and efficacy of an investigational NRTI- and RTV-sparing regimen of atazanavir (ATV) experimental dose of 300mg bid plus raltegravir (RAL) 400mg BID (ATV+RAL) in treatment-naïve HIV-infected subjects (#THLBB204).Presented at: XVIII International AIDS Conference. Vienna, Austria, 18-23 July 2010.
86. Colonno R, Rose R, Mclaren C, Thiry A, Parkin N, Friborg J: Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens. J. Infect. Dis. 189(10), 1802-1810 (2004). (Pubitemid 38657216)
87. Weinheimer S, Discotto L, Friborg J, Yang H, Colonno R: Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones. Antimicrob. Agents Chemother. 49(9), 3816-3824 (2005). (Pubitemid 41233037)
88. Cohen C, Nieto-Cisneros L, Zala C et al.: Comparison of atazanavir with lopinavir ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial. Curr. Med. Res. Opin. 21(10), 1683-1692 (2005). (Pubitemid 41505034)
89. Rotger M, Taffe P, Bleiber G et al.: Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J. Infect. Dis. 192(8), 1381-1386 (2005). (Pubitemid 41401151)
90. Zhang D, Chando TJ, Everett DW, Patten CJ, Dehal SS, Humphreys WG: In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab. Dispos. 33(11), 1729-1739 (2005). (Pubitemid 41539973)
91. Pérez-Elías MJ, Gatell JM, Flores J et al.: Short-term effect of ritonavir-boosted atazanavir in hepatitis B and/or C co-infected, treatment-experienced HIV patients. HIV Clin. Trials 10(4), 269-275 (2009).
92. Torti C, Lapadula G, Antinori A et al.: Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian atazanavir expanded access program and master cohorts. Infection 37(3), 244-249 (2009).
93. Sulkowski MS: Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. Clin. Infect. Dis. 38(Suppl. 2), S90-S97 (2004). (Pubitemid 38328170)
94. Rodríguez-Nóvoa S, Morello J, González M et al.: Increase in serum bilirubin in HIV/ hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin. AIDS 22(18), 2535-2537 (2008).
95. Guillemi S, Harris M, Kanters S et al.: Can total bilirubin levels be used to predict high atazanavir trough concentration among HIV+ adults receiving ritonavir-boosted atazanavir? (#THPE0159).Presented at: XVIII International AIDS Conference. Vienna, Austria, 18-23 July 2010.
96. Rodriguez-Novoa S, Morello J, Barreiro P et al.: Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring. AIDS Res. Hum. Retroviruses 24(6), 821-825 (2008). (Pubitemid 351871672)
97. Anderson PL, Lichtenstein KA, Gerig NE, Kiser JJ, Bushman LR: Atazanavir-containing renal calculi in an HIV-infected patient. AIDS 21(8), 1060-1062 (2007). (Pubitemid 46684345)
98. Chan-Tack KM, Truffa MM, Struble KA, Birnkrant DB: Atazanavir-associated nephrolithiasis: cases from the US food and drug administrations adverse event reporting system. AIDS 21(9), 1215-1218 (2007). (Pubitemid 46763296)
99. Izzedine H, Mrad MB, Bardier A, Daudon M, Salmon D: Atazanavir crystal nephropathy. AIDS 21(17), 2357-2358 (2007).
100. Pacanowski J, Poirier J-M, Petit I, Meynard J-L, Girard P-M: Atazanavir urinary stones in an HIV-infected patient. AIDS 20(16), 2131 (2006). (Pubitemid 44611073)
101. Gavazzi G, Bouchard O, Leclercq P et al.: Change in transaminases in hepatitis C virus- and HIV-coinfected patients after highly active antiretroviral therapy: differences between complete and partial virologic responders? AIDS Res. Hum. Retroviruses 16(11), 1021-1023 (2000). (Pubitemid 30461040)
102. Murphy Rl, Berzins B, Zala C et al.: Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy. AIDS 24(6), 885-890 (2010).
103. Gatell J, Salmon-Ceron D, Lazzarin A et al.: Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: Tthe SWAN study (AI424-097) 48-week results. Clin. Infect. Dis. 44(11), 1484-1492 (2007). (Pubitemid 46801594)
104. Mallolas J, Podzamczer D, Milinkovic A et al.: Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/R-containing haart: the ATAZIP study. J. Acquir. Immune Defic. Syndr. 51(1), 29-36 (2009).
105. Soriano V, García-Gasco P, Vispo E et al.: Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial. J. Antimicrob. Chemother. 61(1), 200-205 (2008).
106. Stanley TL, Joy T, Hadigan CM et al.: Effects of switching from lopinavir ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in hiv-infected patients. AIDS 23(11), 1349-1357 (2009).
107. Calza L, Manfredi R, Colangeli V et al.: Efficacy and safety of atazanavir-ritonavir plus abacavir-lamivudine or tenofovir-emtricitabine in patients with hyperlipidaemia switched from a stable protease inhibitor-based regimen including one thymidine analogue. AIDS Patient Care STDS 23(9), 691-697 (2009).
108. Sension M, Andrade Neto JL, Grinsztejn B et al.: Improvement in lipid profiles in antiretroviral-experienced HIV-positive patients with hyperlipidemia after a switch to unboosted atazanavir. J. Acquir. Immune Defic. Syndr. 51(2), 153-162 (2009).
109. Tomaka F, Lefebvre E, Sekar V et al.: Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers. HIV Med. 10(5), 318-327 (2009).
110. Aberg J, Overton T, Gupta S, Falcon R, Ryan R, De La Rosa G: METABOLIK (Metabolic Evaluation in Treatment Naives Assessing the Impact of Two Boosted Protease Inhibitors on Lipids and Other Markers): comparison of the metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir over 12 weeks (#WEPE0111) Presented at: XVIII International AIDS Conference. Vienna, Austria, 18-23 July 2010.
111. Mccomsey G, Rightmire A, Wirtz V, Yang R, Mathew M, Mcgrath D: Changes in body composition with ritonavir-boosted and unboosted atazanavir treatment in combination with lamivudine and stavudine: a 96-week randomized, controlled study. Clin. Infect. Dis. 48(9), 1323-1326 (2009).
112. Busti AJ, Bedimo R, Margolis DM, Hardin DS: Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated adult male patients after switch to atazanavir/ritonavir. J. Investig. Med. 56(2), 539-544 (2008).
113. Noor MA, Flint OP, Maa J-F, Parker RA: Effects of atazanavir/ritonavir and lopinavir ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS 20(14), 1813-1821 (2006). (Pubitemid 44358899)
114. La Porte CJ, Back DJ, Blaschke T et al.: Updated guideline to perform therapeutic drug monitoring for antiretroviral agents. Rev. Antivir. Ther. 3, 4-14 (2006).